ABSK112

News alerts, weekly reports and conference planners

Company:

Abbisko

Drug class:

2years

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)

P1, N=164, Recruiting, Abbisko Therapeutics Co, Ltd

2 years ago

New P1 trial

ABSK112

almost3years

Discovery and characterization of ABSK112, a next-generation and potential best-in-class EGFR Exon20 mutant inhibitor with superior selectivity and brain penetration ability (AACR 2023)

Kinome selectivity, safety profiles, PK and ADME profiles were also characterized. ABSK112 showed potent inhibition of proliferation in multiple EGFR Exon20 mutation cell lines and superior wild-type EGFR selectivity compare to other inhibitors including mobocertinib (TAK788). ABSK112 is a novel and next-generation EGFR Exon20 mutation inhibitor with improved selectivity over wild-type EGFR and strong brain penetrating ability. It has demonstrated superior in vivo efficacy in several xenograft models with various EGFR Exon20 mutations, and excellent drug-like properties supporting its further development into clinical studies.

almost 3 years ago

Late-breaking abstract • EGFR exon 20

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR exon 20 insertion • EGFR wild-type • EGFR exon 20 mutation

Exkivity (mobocertinib) • ABSK112